California Public Employees Retirement System cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 4.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 830,209 shares of the company’s stock after selling 35,888 shares during the period. California Public Employees Retirement System owned about 0.17% of Elanco Animal Health worth $19,867,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Parallel Advisors LLC lifted its position in shares of Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after buying an additional 392 shares in the last quarter. Lazard Asset Management LLC increased its holdings in Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in Elanco Animal Health by 4.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares during the period. Finally, Bessemer Group Inc. raised its stake in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the period. Institutional investors own 97.48% of the company’s stock.
Elanco Animal Health Price Performance ELAN stock opened at $25.41 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company’s fifty day moving average price is $23.85 and its 200-day moving average price is $23.95. Elanco Animal Health Incorporated has a one year low of $13.39 and a one year high of $27.72. The company has a market capitalization of $12.69 billion, a PE ratio of -50.81, a price-to-earnings-growth ratio of 1.67 and a beta of 1.68.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth A number of equities analysts have weighed in on the stock. Citigroup upped their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. TD Cowen raised their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Finally, JPMorgan Chase & Co. increased their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.73.
Check Out Our Latest Stock Analysis on ELAN
Insider Transactions at Elanco Animal Health In other news, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.14% of the company’s stock.
Elanco Animal Health Profile (Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Further Reading Five stocks we like better than Elanco Animal Health Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia Public Employees Retirement System Buys New Stake in CoreWeave Inc. $CRWV
NEXT HEADLINE »California Public Employees Retirement System Sells 13,197 Shares of Core & Main, Inc. $CNM
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Elanco Animal Health Incorporated (ELAN - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Elanco Animal Health Incorporated currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for ELAN that show why this company shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For ELAN, shares are up 4.07% over the past week while the Zacks Medical - Outpatient and Home Healthcare industry is up 1.41% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 9.92% compares favorably with the industry's 10.34% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Elanco Animal Health Incorporated have increased 15.03% over the past quarter, and have gained 70.66% in the last year. In comparison, the S&P 500 has only moved 6.61% and 20.33%, respectively.
Investors should also pay attention to ELAN's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. ELAN is currently averaging 4,014,582 shares for the last 20 days.
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with ELAN.
Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost ELAN's consensus estimate, increasing from $1.10 to $1.11 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been 1 downward revision in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that ELAN is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Elanco Animal Health Incorporated on your short list.
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:
Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii , /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i
Newly Published Data Found Credelio Quattro:
Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. Faster2 Tick1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off. Rapid kill is critical for preventing Lyme disease transmission, which typically occurs 24-48 hours after attachment.i "Speed of kill is a critical factor for veterinarians and pet owners when choosing parasite coverage because the longer a tick is attached, the more likely it is to transmit dangerous diseases, like Lyme disease, to pets," said Dr. Casey Locklear, veterinarian and leading parasiticides expert at Elanco. "These results reinforce that lotilaner, the active ingredient in Credelio Quattro, not only starts working fast but maintains its speed of kill4 against multiple species of ticks5, providing veterinarians and pet owners with the confidence that their dogs are protected from the very start of the month to the very end."
The black-legged tick is the primary vector for Borrelia burgdorferi, the bacterium responsible for Lyme disease and anaplasmosis. The study, which evaluated the speed of kill against Ixodes scapularis (black-legged tick), found that Credelio Quattro was the only product tested to achieve significant initial tick reduction2 within just 8 hours of infestation. Notably, this rapid speed of kill1 was maintained from the beginning of the month through Day 28, providing consistent protection for the entire dosing interval.i
"Ticks are on the move. They are no longer limited to the places or seasons where we have historically expected to find them," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "As their geographic range expands, so does the risk of tick bites and exposure to the pathogens they carry. Because tick-borne diseases can threaten the health of people, pets, and livestock, raising public awareness is more important than ever as tick populations grow and spread into new regions."
The findings are based on evaluation time points at 4, 8, 12, 24, and 48 hours post-treatment and reinfestation. The data demonstrates that Credelio Quattro outperforms Simparica Trio and NexGard Plus in rapid tick1 reduction, particularly in the critical first 8 to 12 hours.i
Speed of kill against Ixodes scapularis (black-legged tick)^ i
Time point at which active achieved consistent superior efficacy vs. untreated control group¥
Day of Study
Credelio Quattro
(lotilaner, moxidectin, praziquantel, and pyrantel)
Simparica Trio
(sarolaner, moxidectin and pyrantel)
NexGard Plus
(afoxolaner, moxidectin, and pyrantel)
0
8 hrs
12 hrs
12 hrs
21
8 hrs
24 hrs
24 hrs
28
8 hrs
12 hrs
24 hrs
^Tick counts were evaluated at all 4-, 8-, 12-, 24-, and 48-hour time points as part of the study design
¥P<0.05.
Credelio Quattro also has a U.S. Food and Drug Administration approved claim for prevention of Lyme disease in dogs as a direct result of killing black-legged ticks.
Does Credelio Quattro Kill the Lone Star Tick?
Credelio Quattro is approved to protect dogs from the lone star tick (Amblyomma americanum), and its active ingredient, lotilaner, also has the fastest3 initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ii This aggressive and expanding tick species – established across the South, Midwest and Northeast, and continuing to spread – is one of the hardest to kill and is best known for its association with alpha-gal syndrome, or the red meat allergy in humans. It can also transmit dangerous disease-causing pathogens to dogs.iii A 2024 head-to-head study published in Parasites & Vectors compared lotilaner, the active ingredient in Credelio (lotilaner) and Credelio Quattro with sarolaner in Simparica Trio and afoxolaner in NexGard®, and found that lotilaner kills the lone star tick faster4 than sarolaner in Simparica Trio and afoxolaner in NexGard, protecting dogs against this pathogen-carrying tick.
Speed of kill against Amblyomma americanum (lone star tick)^ ii
Time point at which active achieved consistent superior efficacy vs. untreated control group¥
Day of Study
Credelio
(lotilaner)
Sarolaner
(sarolaner, moxidectin and pyrantel)
NexGard
(afoxolaner)
0
12 hrs
24 hrs
24 hrs
21
12 hrs
48 hrs
48 hrs
28
8 hrs
48 hrs
72 hrs
^Tick counts were evaluated at all 4-, 8-, 12-, 24-, 48-, and 72-hour time points as part of the study design
¥P<0.05.
"With a heavier tick season and emergency room visits from tick bites on the riseiv, pet owners should remain vigilant and keep their pets on year-round parasite coverage," Dr. Locklear notes. "We continue to look for opportunities to make parasite protection stronger and evolve research around best-in-class medicines."
Frequently Asked Questions About Ticks and Credelio Quattro:
How fast does Credelio Quattro kill ticks?
Studies show that lotilaner, the active ingredient in Credelio Quattro kills ticks5 faster6 than the competition.i,ii A 2026 study published in Parasites & Vectors shows that Credelio Quattro achieved significant reduction2 of black-legged ticks within 8 hours of infestation.i A 2024 study shows that lotilaner, the active ingredient in Credelio and Credelio Quattro also has the fastest3 initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ii
Why is it important to kill ticks quickly?
The risk of disease transmission increases the longer a tick remains attached, making rapid speed of kill a critical factor in preventing the transmission of disease. A 2026 study shows that Credelio Quattro was the only product tested that significantly reduced2 black-legged ticks within 8 hours.i
Does Credelio Quattro lose effectiveness to kill ticks1 quickly at the end of the month?
No. The data shows that Credelio Quattro maintains its 8-hour speed of kill2 on Day 28, whereas competitors showed a decline in performance.i
Are black-legged ticks linked to the red meat allergy in humans?
In the United States, alpha-gal syndrome, or red meat allergy, is usually associated with bites from the lone star tick (Amblyomma americanum); however, two Emerging Infectious Diseases studies link bites from black-legged ticks (deer ticks) and western black-legged ticks to potentially life-threatening alpha-gal syndrome.v Additional work will be needed to determine a possible link, according to the researchers, but this continues to put emphasis on the need for tick bite protection for humans.
To learn more about Credelio Quattro visit CredelioQuattroVet.com.
PM-US-26-1188
Ixodes scapularis (black-legged tick) Based on the time to statistical significance vs. control in a head-to-head study on Day 0 post-treatment and Day 28 for reinfestations comparing Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against Ixodes scapularis. Based on the time to statistical significance vs. control in a head-to-head study comparing Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner). Based on the time to statistical significance vs control in two separate head-to-head studies. The first study compared Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner) against Amblyomma americanum. The second study compared Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against I. scapularis. Ixodes scapularis (black-legged tick) and Amblyomma americanum (lone star tick) NexGard and NexGard Plus are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. Simparica Trio is a registered trademark of Zoetis Services LLC.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Indications for Credelio Quattro/Credelio Quattro-CA1
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.
Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information for Credelio Quattro/Credelio Quattro-CA1
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.
Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.
For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.
Indications for Credelio
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.
Important Safety Information for Credelio
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.
i Reif, K.E., Kollasch, T.M., Locklear, C.L. et al. Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard® PLUS), or lotilaner (Credelio Quattro™). Parasites Vectors (2026). https://doi.org/10.1186/s13071-026-07559-y
ii Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313.
iii Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from https://www.cdc.gov/ticks/about/where-ticks-live.html
iv CDC Data Show Weekly ER Visits for Tick Bites Higher Than Usual." Centers for Disease Control and Prevention, 23 Apr. 2026,
v Van Beusekom, Mary. "Research Ties Bites from 2 More Types of Ticks to Red Meat Allergy." CIDRAP (Center for Infectious Disease Research and Policy), 4 Apr. 2025
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Media Contact: Season Solorio (765) 316-0233 [email protected]
Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,871,561 shares of the company’s stock, valued at approximately $66,390,000. Allspring Global Investments Holdings LLC owned 0.58% of Elanco Animal Health as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. NewEdge Advisors LLC raised its holdings in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares during the period. Root Financial Partners LLC increased its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $41,000. Torren Management LLC purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $46,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Elanco Animal Health by 43.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after acquiring an additional 938 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.
Elanco Animal Health Stock Performance NYSE:ELAN opened at $25.84 on Friday. The firm has a market capitalization of $12.91 billion, a PE ratio of -51.68, a price-to-earnings-growth ratio of 1.70 and a beta of 1.68. The business’s fifty day moving average price is $23.63 and its 200 day moving average price is $23.89. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.
Insider Buying and Selling at Elanco Animal Health In other news, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth A number of equities research analysts have recently weighed in on the company. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Citigroup increased their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. increased their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, TD Cowen raised their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $28.55.
Check Out Our Latest Report on ELAN
About Elanco Animal Health (Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Featured Stories Five stocks we like better than Elanco Animal Health AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAngeles Wealth Management LLC Grows Stock Position in Palo Alto Networks, Inc. $PANW
NEXT HEADLINE »Robinhood Markets, Inc. $HOOD Position Trimmed by Allspring Global Investments Holdings LLC
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Elanco Animal Health Incorporated (ELAN - Free Report) . This company, which is in the Zacks Medical - Outpatient and Home Healthcare industry, shows potential for another earnings beat.
This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 17.91%.
For the last reported quarter, Elanco Animal Health came out with earnings of $0.4 per share versus the Zacks Consensus Estimate of $0.34 per share, representing a surprise of 17.65%. For the previous quarter, the company was expected to post earnings of $0.11 per share and it actually produced earnings of $0.13 per share, delivering a surprise of 18.18%.
Price and EPS Surprise
For Elanco Animal Health, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Elanco Animal Health has an Earnings ESP of +5.00% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on August 5, 2026.
When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shortly following the call.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investors in Elanco Animal Health Incorporated (ELAN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2026 $17.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Elanco Animal Health share, but what is the fundamental picture for the company? Currently, Elanco Animal Health is a Zacks Rank #3 (Hold) in the Medical - Outpatient and Home Healthcare Industry that ranks in the Top 27% of our Zacks Industry Rank. Over the last 60 days, no analyst has increased his estimate for the current quarter, while six have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter to move from 30 cents per share to 27 cents per share in the same time period.
Given the way analysts feel about Elanco Animal Health right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions
, /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health.
To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector.
Elanco Ventures "From pets to protein – the animal health industry has never been more relevant than it is today," said Jeff Simmons, President and CEO of Elanco. "Innovation is happening outside of the boundaries of any single company. Elanco Ventures allows us to strategically leverage the startup landscape to expand our visibility into a range of emerging technologies that help us meet pet owners' evolving expectation of care and the increasing global demand for protein."
While primarily focused on animal health, the fund may also explore opportunities within the broader One Health landscape. It will also leverage the proximity of partnerships within the One Health Innovation District in Indianapolis, anchored by Elanco and Purdue University, and designed to bring together life sciences, researchers, and entrepreneurs in one place to break innovation barriers and accelerate progress.
"Elanco Ventures embodies our commitment to partnership and innovation," said Tim Bettington, Executive Vice President, Center of Strategic Growth at Elanco. "By identifying promising startup technologies and collaborating with the One Health Innovation District, we are better positioned to fast-track innovation that can redefine the future of animal health."
Launching in late 2026, Elanco Ventures will be overseen by Eric Steager, an experienced CVC leader, and focus on early-stage companies, prioritizing Pre-Seed, Seed and Series A stages of development.
About the One Health Innovation District
The One Health Innovation District is a first-of-its-kind, purpose-built ecosystem where animal, human, and plant health intentionally converge in one connected place. Anchored by industry, research, diagnostics, care, commercialization, and talent, the district is designed to accelerate discovery to delivery and advance the future of One Health through speed, connection, and shared purpose.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for pets Features proprietary PureFil™ Technology, designed to reduce vaccination reactions associated with unwanted proteini,ii,iii Product expected to begin shipping in the next 30 days , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health.
As an expansion of the TruCan Ultra line, this new 1/2 mL formulation provides the same broad protection as the category-exclusive 1 mL version but in half the volume. This combination formulation allows veterinarians to provide essential protection without the need for multiple injections.
TruCan Ultra Lyme-L4 is engineered with Elanco's proprietary PureFilTM Technology, designed to reduce vaccination reactions associated with unwanted protein, allowing clinicians to support patient comfort without compromising on protection.i,ii,iii
"USDA approval of TruCan Ultra Lyme-L4 is a testament to our commitment to vaccine innovation," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "By offering a low-volume, highly-purified combination vaccine, we are providing veterinarians with a powerful tool to help close critical protection gaps while encouraging a comfortable, low-stress experience."
This approval comes at a critical time for canine wellness as all dogs are at risk for leptospirosis regardless of breed, size, lifestyle, or geographic location.iv Leptospirosis is now recognized as a core vaccine per American Animal Hospital Association (AAHA) guidelines,v meaning all dogs should be vaccinated. Additionally, the risk of Lyme disease is spreading to new geographies; however, recent data show a significant "protection gap," with over 40% of at-risk dogs in endemic states lacking a current Lyme vaccine, despite having received their core vaccines.vi
"Leptospirosis and Lyme disease remain important infectious threats for dogs in the U.S.," says Dr. Jessica Pritchard, Clinical Assistant Professor in Small Animal Internal Medicine at the University of Wisconsin-Madison School of Veterinary Medicine, "Leptospirosis vaccination is now considered core for dogs because the exposure risk exists nationwide, including in suburban and urban environments. Vaccination, along with risk-based lifestyle discussions between veterinarians and pet owners, plays an important role in protecting dogs from these preventable diseases."
TruCan Ultra Lyme vaccines have demonstrated 92.2% efficacy against natural infection in highly endemic areasvii and 100% efficacy in laboratory studies.viii By reducing the number of injections required—one "poke" versus two—the combination vaccine is designed to improve the overall wellness visit for pets, owners and veterinary staff.
This approval follows recent USDA approvals of TruCan Ultra B (Oral), the first 1/2 mL oral Bordetella vaccine, and TruCan Ultra CIV H3N2/H3N8, the only 1/2 mL bivalent canine influenza vaccine. Together, these advancements add to a comprehensive suite of low-volume, highly purified vaccines that allow veterinary teams to tailor immunization protocols to the specific needs of every dog.
TruCan Ultra Lyme-L4 is expected to begin shipping in the next 30 days. To learn more about TruCan Ultra Lyme-L4 visit https://my.elanco.com/us/trucan.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
i Elanco Animal Health. Data on File. REF-29478
ii Franco J, Aryal UK, HogenEsch H, Moore GE. Proteomic analysis of canine vaccines. Am J Vet Res. 2023;84(3):ajvr.22.11.0192. Published 2023 Jan 24. doi:10.2460/ajvr.22.11.0192
iii Ohmori K, Masuda K, Maeda S, et al. IgE reactivity to vaccine components in dogs that developed immediate type allergic reactions after vaccination. Vet Immunol Immunopathol. 2005;104(3–4):249–256. doi:10.1016/j.vetimm.2004.12.003
iv Sykes JE, Francey T, Schuller S, Stoddard RA, Cowgill LD, Moore GE. Updated ACVIM consensus statement on leptospirosis in dogs. J Vet Intern Med. 2023 Nov-Dec;37(6):1966-1982. doi: 10.1111/jvim.16903
v AAHA Guidelines
vi Malter KB, et al. Vaccine 2022
vii Levy SA. Vet Ther 2002
viii Elanco Data on File. REF-04031
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Media Contact: Season Solorio (765) 316-0233 [email protected]
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Davidson Investment Advisors decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 24.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 680,867 shares of the company’s stock after selling 223,234 shares during the period. Davidson Investment Advisors owned approximately 0.14% of Elanco Animal Health worth $15,408,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Elanco Animal Health by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after purchasing an additional 759,623 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Elanco Animal Health by 8.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after purchasing an additional 1,962,276 shares in the last quarter. UBS Group AG boosted its position in shares of Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Elanco Animal Health by 48.0% during the 3rd quarter. Northern Trust Corp now owns 4,291,618 shares of the company’s stock valued at $86,433,000 after purchasing an additional 1,391,697 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.
Elanco Animal Health Stock Down 0.0% Shares of NYSE:ELAN opened at $23.68 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The company has a market cap of $11.77 billion, a PE ratio of -49.33, a price-to-earnings-growth ratio of 3.02 and a beta of 1.88. Elanco Animal Health Incorporated has a 52 week low of $8.33 and a 52 week high of $27.72. The firm has a 50 day simple moving average of $24.34 and a 200 day simple moving average of $23.13.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.
Wall Street Analyst Weigh In Several equities analysts have recently weighed in on ELAN shares. KeyCorp raised their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Leerink Partners raised their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Finally, Citigroup assumed coverage on shares of Elanco Animal Health in a report on Wednesday, April 15th. They issued a “buy” rating and a $30.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average price target of $27.90.
View Our Latest Stock Analysis on ELAN
Elanco Animal Health Company Profile (Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Read More Five stocks we like better than Elanco Animal Health Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDavidson Investment Advisors Trims Holdings in Cigna Group $CI
NEXT HEADLINE »Davidson Investment Advisors Purchases 16,838 Shares of VanEck Intermediate Muni ETF $ITM
/C O R R E C T I O N – Elanco Animal Health/ In the news release, Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock, issued 27-Apr-2026 by Elanco Animal Health over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock Action Prepares Veterinarians and Livestock Producers with Prevention and Treatment Options Prior to Fly Being Detected in the U.S.
Federal agencies grant emergency authorizations for New World screwworm in livestock, reinforcing Elanco's leadership in livestock health innovations Actions underscore the commitment of the U.S. Food and Drug Administration, U.S. Environmental Protection Agency, and U.S. Department of Agriculture to act swiftly against emerging animal health threats Early detection and immediate treatment of open wounds on livestock is critical to prevention of New World screwworm myiasis in individual animals and rapid spread of the pest An effective fly and tick control regimen is also essential, helping to avoid small bites on animals that can be an entry point for the screwworm , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Negasunt Powder (coumaphos, propoxur, sulfanilamide topical powder) and a Section 18 Emergency Exemption from the U.S. Environmental Protection Agency (EPA) in cooperation with the United States Department of Agriculture (USDA) for Tanidil (coumaphos, propoxur) for the prevention and treatment of New World screwworm infestations in a variety of livestock species.
With confirmed cases of New World screwworm detected as close as 62 miles south of the U.S.-Mexico borderi, these authorizations ensure veterinarians and livestock producers have a ready-now treatment option for various livestock species should the fly enter the U.S.
Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.
With more than 70 years of on-farm experience, Elanco is standing alongside livestock producers and regulators during this challenging time by providing New World screwworm options for prevention and treatment of New World screwworm infestations, education and science-based resources if the fly enters the U.S.
"We appreciate our federal agencies' swift review of the scientific data demonstrating that these products may be effective in prevention and treatment against New World screwworm infestations," said Dr. Ellen de Brabander, Executive Vice President of Research & Development at Elanco. "We're committed to working alongside state and federal regulatory authorities to provide our support and scientific expertise. These emergency authorizations provide new, science-based solutions and treatment options to livestock producers, veterinarians, and other animal health industry stakeholders at a time when they need them most."
Effective Parasite Protection is Paramount
Elanco now offers producers and veterinarians several key products that can help prevent and treat New World screwworm infestations in a variety of livestock species. In addition to the EUA for Negasunt Powder and the Section 18 Emergency Exemption for Tanidil, the company also offers Catron IV – one of the few EPA registered products labeled for treatment against screwworm in a variety of livestock species. This screwworm and ear tick spray can help producers kill and control screwworm flies and maggots on beef and dairy cattle, sheep, goats, hogs and horses.
"The most important thing producers can do is self-education. They should be learning more about New World screwworm from credible sources, staying current with treatment protocol recommendations, and knowing where active cases are located," said Dr. M. Wayne Ayers, Elanco Sr. Technical Consultant and veterinarian. "The second most important part of preventing losses from New World screwworm is for producers to keep their 'eyes on livestock.' Looking over livestock as frequently as possible will allow early detection and treatment of infestation. Early intervention is key to minimizing tissue damage, decreasing mortality, and reducing the risk to the area by preventing the fly's potential offspring from completing their lifecycle."
Preventing Wound-Causing Parasites Also Essential
According to APHIS, an important way to prevent New World screwworm infestation is to protect livestock from other wound-causing parasites such as biting flies and ticks.ii
"Some of the surgical and care procedures we perform for livestock could result in potential sites for the female screwworm to deposit her eggs," said Dr. Ayers. "Wounds as small as fly and tick bites are potential areas to watch for as well. Therefore, treating open wounds, including those from surgical sites, and instituting a good fly and tick prevention program will play an important role in reducing the number of infestations we may see."
Elanco offers several EPA registered products to help control flies and ticks on livestock in the forms of pour-on liquids, sprays, dusts and ear tags.
Elanco recommends that livestock producers and veterinarians review the latest resources available from the USDA and FDA and consider the additional resources below in advance of the potential entry of New World screwworm into the United States.
To learn more about New World screwworm (NWS) using the following resources:
USDA NWS Alert and Fact Sheet NCBA NWS Resources FDA Information for Veterinarians on NWS Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)
WARNING: Neurotoxicity. Read full Fact Sheet for complete information.
Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing. Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters. This product is toxic to mammals, birds, fish, and aquatic invertebrates. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.
For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).
For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.
Limitations of Authorized Use
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.
Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.
A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.
A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.
Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.
To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.
Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.
Federal law prohibits the extra-label use of this drug.
Additional Important Safety Information
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.
Important Information about Tanidil
Tanidil™ is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.
For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.
Read the entire label. This product must be used strictly in accordance with this label's precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.
Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.
ABOUT ELANCO
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Media Contact: Season Solorio (765) 316-0233 [email protected]
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both Addus HomeCare (ADUS) and Elanco Animal Health Incorporated (ELAN). But which of these two stocks presents investors with the better value opportunity right now?
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target
First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth Reported Net Income of $57 million, Adjusted Net Income of $204 million Adjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5% Reported EPS of $0.11, Adjusted EPS of $0.40 Net leverage ratio of 3.5x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.2 billion Raising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growth Raising Adjusted EBITDA to $975 million to $1,005 million, a year-over-year increase of 10% at midpoint Raising Adjusted EPS of $1.03 to $1.09, a year-over-year increase of 13% at midpoint Improving year-end net leverage ratio target to 3.0x to 3.2x Adjusted EBITDA , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2026, provided guidance for the second quarter of 2026, and updated guidance for the full year 2026.
"Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons, President and CEO of Elanco. "Organic constant currency revenue growth of 10% reflects outperformance across our diverse portfolio, including Zenrelia reaching trailing 4-quarter blockbuster status, and Credelio Quattro achieving accelerating market share gains. All major species grew, driven by our basket of innovation and growth in our base business. We are improving our full year guidance across all key metrics, as our consistent execution is creating more ways for Elanco to win in this durable, attractive animal health industry."
Select Business Highlights Since the Last Earnings Call
Credelio Quattro™ accelerated dollar share gains of broad-spectrum sales out of U.S. vet clinics in Q1, up 3 points versus Q4**; penetrated over 40% of the U.S. clinic base; 53% share in U.S. clinics that carry Quattro, up 13 points in Q1 versus Q4**; launched in Australia and approved in Canada, both in April Zenrelia™ achieved trailing 4-quarter blockbuster status; over 2 million dogs have been treated; efficacy driving use in over 50% of U.S. clinics with U.S. JAK market share up 5 points versus Q4**; over 50% share of JAK market in Brazil, over 35% share in Japan, and high-teens to 30%+ JAK market share in key European markets*** Befrena™ phased launch approach on track, with product already shipped to early experience influencers and in use, and commercialization in the U.S. expected in Q2 Added Costco and Dollar General as new retail customers for parasiticides in the U.S. Advantage® Collar for Dogs launched in April, providing four-month protection against fleas and ticks, available at pet specialty, dollar, grocery, and mass retailers Closed the previously announced acquisition of AHV International on April 30th **Per Kynetec data
***Internal estimates based on multiple data sources
Financial Results
First Quarter Results
(dollars in millions, except per share amounts)
2026
2025
Change (%)
Organic CC
Growth (1) (%)
Pet Health
$710
$635
12 %
7 %
Farm Animal
$642
$546
18 %
13 %
Cattle
$316
$272
16 %
13 %
Poultry
$230
$189
22 %
16 %
Swine
$96
$85
13 %
9 %
Contract Manufacturing and Other (2)
$19
$12
58 %
Total Revenue
$1,371
$1,193
15 %
10 %
Gross Profit
$785
$684
15 %
Reported Net Income
$57
$67
(15) %
Adjusted EBITDA
$334
$276
21 %
Reported EPS
$0.11
$0.13
(15) %
Adjusted EPS
$0.40
$0.37
8 %
(1) Organic CC Growth = Represents revenue growth excluding royalty revenue that was sold to a third party and the impact of foreign exchange rates.
(2) Primarily represents revenue from arrangements in which we manufacture products on behalf of a third party and royalty revenue. Royalty revenue sold to a third party, to which we are no longer entitled but is still required to be recognized as revenue under GAAP, totaled $9 million for the three months ended March 31, 2026.
In the first quarter of 2026, revenue was $1,371 million, an increase of 15% on a reported basis, or 10% on an organic constant currency basis, compared to the first quarter of 2025.
Pet Health revenue was $710 million, an increase of 12% on a reported basis, or 7% on an organic constant currency basis. The year over year volume increase of 5% in the first quarter was primarily driven by new products, and the addition of two new retail customers benefitting parasiticides. The 2% increase from price was in line with the company's expectation. The Advantage® Family of products and Seresto® contributed revenue of $163 million and $159 million , respectively.
Farm Animal revenue was $642 million, an increase of 18% on a reported basis, or 13% on an organic constant currency basis. First quarter volumes were up 11%, driven by strong demand across all species, led by poultry and ruminants. Farm animal organic constant currency revenue growth included a 2% increase from price, compared to the first quarter of 2025.
Gross profit was $785 million in the first quarter of 2026, and gross margin percentage was 57.3% in the first quarter of 2026 and 2025. On an adjusted basis, gross profit was $776 million and gross margin percentage was 57.0% in the first quarter of 2026, a 40 basis point decrease compared to the first quarter of 2025 as expected. The decrease in gross margin percentage on an adjusted basis was primarily driven by product mix with strong Farm Animal growth, the timing of inflation, and a flow through of higher inventory costs, partially offset by price and sales volume benefits.
Total operating expenses were $478 million for the first quarter of 2026, an increase of 10% compared to the first quarter of 2025. Marketing, selling and administrative expenses increased 12% to $381 million, driven by higher compensation expense, foreign currency exchange rate movements and strategic investments in the global launches of new products, partially offset by decreased expenses in certain general and administrative expenses. Research and development expenses increased 3% to $97 million driven primarily by foreign exchange rates.
Asset impairment, restructuring and other special charges were $16 million in the first quarter of 2026, compared to $9 million in the first quarter of 2025. Charges recorded in the first quarter of 2026 primarily related to $15 million of non-cash shut-down costs for the animal studies portion of our R&D facilities in Monheim, Germany. Charges recorded in the first quarter of 2025 primarily consisted of upfront payments made in relation to new licensing arrangements.
Reported net interest expense was $57 million in the first quarter of 2026, an increase of $17 million compared to the first quarter of 2025. The increase was principally due to imputed interest on our liability for sale of future revenue of $14 million, as well as interest expense related to our corporate headquarters finance lease, partially offset by lower average debt balances. Adjusted net interest expense, which excludes this imputed interest, was $43 million in the first quarter of 2026, an increase of $3 million compared to the first quarter of 2025.
The reported effective tax rate was 34.6% in the first quarter of 2026 compared to (12.2)% in the first quarter of 2025. The adjusted effective tax rate was 21.2% in the first quarter of 2026 compared to 9.2% in the first quarter of 2025.
Net income for the first quarter of 2026 was $57 million, or $0.11 per diluted share on a reported basis, compared with net income of $67 million, or $0.13 per diluted share, for the same period in 2025. On an adjusted basis, net income for the first quarter of 2026 was $204 million, or $0.40 per diluted share, an 8% increase compared with the same period in 2025.
Adjusted EBITDA was $334 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025. Adjusted EBITDA margin was 24.5% compared with 23.1% for the first quarter of 2025.
Working Capital and Balance Sheet
Cash provided by operations was $13 million in the first quarter of 2026, compared to cash used in operations of $4 million in the first quarter of 2025.
As of March 31, 2026, Elanco's net leverage ratio was 3.5x adjusted EBITDA, a decrease of 0.1x compared to December 31, 2025.
Financial Guidance
Elanco is updating financial guidance for the full year 2026, summarized in the following table.
2026 Full Year
(dollars in millions, except per share amounts)
February
Guidance
May
Guidance
Revenue (1)
$4,950
to
$5,020
$5,010
to
$5,085
Adjusted EBITDA
$955
to
$985
$975
to
$1,005
Adjusted Earnings per Share
$1.00
to
$1.06
$1.03
to
$1.09
(1) Revenue guidance excludes royalty revenue that was sold to a third party.
"Our strong first quarter results underscore the powerful momentum we are carrying into 2026," said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. "This outperformance, driven by both volume and price, gives us the confidence to raise our full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, while continuing to take a prudent, balanced approach in a dynamic macro environment. We remain disciplined in our execution of Elanco Ascend, which is already delivering meaningful efficiencies and positions us for significant, sustainable margin expansion starting this year. With accelerating free cash flow and an improved net leverage target, Elanco is operating from a position of financial strength to drive long-term shareholder value."
The company anticipates a tailwind to revenue of approximately $60 million from the favorable impact of foreign exchange rates compared to prior year. Excluding the impact of foreign exchange rates and royalty revenue sold to a third party, the company now expects revenue growth of 5% to 7% versus 4% to 6% previously. The company continues to expect an accelerating contribution from price versus 2025.
Elanco continues to expect adjusted gross margin of 55.1% to 55.5%, an increase of 40 basis points versus 2025. Adjusted EBITDA guidance reflects savings from the Elanco Ascend initiative as well as incremental strategic investments in the global launches of the company's innovation portfolio and the advancement of the R&D pipeline.
Additionally, the company is providing guidance for the second quarter of 2026, as summarized in the following table:
2026 Second Quarter
(dollars in millions, except per share amounts)
Guidance
Revenue (1)
$1,300
to
$1,325
Adjusted EBITDA
$240
to
$260
Adjusted Earnings per Share
$0.25
to
$0.28
(1) Revenue guidance excludes royalty revenue that was sold to a third party.
In the second quarter, the company anticipates a tailwind to revenue of approximately $10 million from the favorable impact of foreign exchange rates compared to prior year. Excluding the impacts of foreign exchange rates and royalty revenue sold to a third party, the company expects 4% to 6% organic constant currency revenue growth. The company expects operating expenses up approximately 8% year over year in constant currency with incremental support for innovation products.
The 2026 full year and second quarter financial guidance reflects foreign exchange rates as of the end of April. Further details on guidance, including GAAP reported to non-GAAP adjusted reconciliations, are included in the financial tables of this press release and will be discussed on the company's conference call this morning.
WEBCAST & CONFERENCE CALL DETAILS
Elanco will host a webcast and conference call at 8:00 a.m. Eastern Time today, during which company executives will review first quarter financial and operational results, discuss second quarter and full year 2026 financial guidance, and respond to questions from analysts. Investors, analysts, members of the media and the public may access the live webcast and accompanying slides by visiting the Elanco website at https://investor.elanco.com and selecting Events and Presentations. A replay of the webcast will be archived and made available a few hours after the event on the company's website, at https://investor.elanco.com/events-and-presentations/default.aspx#module-event-upcoming.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2026 full year and second quarter guidance and long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following:
operating in a highly competitive industry; the success of our research and development (R&D), regulatory approval and licensing efforts; the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein; competition from generic products that may be viewed as more cost-effective; changes in regulatory restrictions on the use of antibiotics in farm animals; an outbreak of infectious disease carried by farm animals; risks related to the evaluation of animals; consolidation of our customers and distributors; an increased use of alternative distribution channels or changes within existing distribution channels; our dependence on the success of our top products; our ability to complete acquisitions and divestitures and to successfully integrate the businesses we acquire; our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements; manufacturing problems and capacity imbalances, including at our contract manufacturers; fluctuations in inventory levels in our distribution channels; risks related to the use of artificial intelligence in our business; our dependence on sophisticated information technology systems and infrastructure, including the use of third-party, cloud-based technologies, and the impact of outages or breaches of the information technology systems and infrastructure we rely on; the impact of weather conditions, including those related to climate change, and the availability of natural resources; demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern; the loss of key personnel or highly skilled employees; adverse effects of labor disputes, strikes and/or work stoppages; the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that limit our operating flexibility and changes in our credit ratings that lead to higher borrowing expenses and restrict access to credit; changes in interest rates that adversely affect our earnings and cash flows; risks related to the write-down of goodwill or identifiable intangible assets; the lack of availability or significant increases in the cost of raw materials; risks related to foreign and domestic economic, political, legal and business environments; risks related to foreign currency exchange rate fluctuations; risks related to underfunded pension plan liabilities; our current plan not to pay dividends and restrictions on our ability to pay dividends; the potential impact that actions by activist shareholders could have on the pursuit of our business strategies; risks related to tax expense or exposures; actions by regulatory bodies, including as a result of their interpretation of studies on product safety; the possible slowing or cessation of acceptance and/or adoption of our farm animal sustainability initiatives; the impact of increased regulation or decreased governmental financial support related to the raising, processing or consumption of farm animals; risks related to tariffs, trade protection measures or other modifications of foreign trade policy; the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters; challenges to our intellectual property rights or our alleged violation of rights of others; misuse, off-label or counterfeiting use of our products; unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products; insufficient insurance coverage against hazards and claims; compliance with privacy laws and security of information; risks related to environmental, health and safety laws and regulations; and inability to achieve our aspirations or meet the expectations of stakeholders with respect to environmental, social and governance matters. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.
Use of Non-GAAP Financial Measures:
We use non-GAAP financial measures, such as revenue growth excluding the impact of divestitures, foreign exchange rate effects, royalty revenue sold to third party, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted gross profit, adjusted gross margin, net debt and net debt leverage to assess and analyze our operational results and trends as explained in more detail in the reconciliation tables later in this release.
We believe these non-GAAP financial measures are useful to investors because they provide greater transparency regarding our operating performance. Reconciliation of non-GAAP financial measures and reported U.S. generally accepted accounting principles (GAAP) financial measures are included in the tables accompanying this press release and are posted on our website at www.elanco.com. The primary material limitations associated with the use of such non-GAAP measures as compared to GAAP results include the following: (i) they may not be comparable to similarly titled measures used by other companies, including those in our industry, (ii) they exclude financial information and events, such as the effects of an acquisition or divestiture or amortization of intangible assets, that some may consider important in evaluating our performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not exclude all unusual or non-recurring items, which could increase or decrease these measures, which investors may consider to be unrelated to our long-term operations. These non-GAAP measures are not, and should not, be viewed as substitutes for GAAP reported measures. We encourage investors to review our unaudited consolidated financial statements in their entirety and caution investors to use GAAP measures as the primary means of evaluating our performance, value and prospects for the future, and non-GAAP measures as supplemental measures.
Availability of Certain Information
We use our website to disclose important company information to investors, customers, employees and others interested in Elanco. We encourage investors to consult our website regularly for important information about Elanco, including an Investor Overview presentation containing a general overview of the business, which can be found in the Events and Presentations page of our website.
Additional Information
We define innovation revenue as revenue from new products, lifecycle management and certain geographic expansions and business development transactions that is incremental in reference to product revenue in 2020 and does not include the expected impact of cannibalization on the base portfolio.
We define organic constant currency revenue growth as revenue growth excluding royalty revenue that was sold to a third party and the impact of foreign exchange rates.
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated Statements of Operations
(Dollars and shares in millions, except per share data)
Three Months Ended March 31,
2026
2025
Revenue
$ 1,371
$ 1,193
Cost of sales
586
509
Gross profit
785
684
Research and development
97
94
Marketing, selling and administrative
381
341
Amortization of intangible assets
138
128
Asset impairment, restructuring and other special charges
16
9
Interest expense, net of capitalized interest
57
40
Other expense, net
9
12
Income before income taxes
87
60
Income tax expense (benefit)
30
(7)
Net income
$ 57
$ 67
Earnings per share:
Basic
$ 0.11
$ 0.14
Diluted
$ 0.11
$ 0.13
Weighted-average shares outstanding:
Basic
497.7
495.1
Diluted
506.0
499.1
Elanco Animal Health Incorporated
Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information
(Unaudited)
(Dollars and shares in millions, except per share data)
We use non-GAAP financial measures, such as organic constant currency revenue growth, adjusted gross profit, adjusted gross margin percentage, adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA and adjusted EBITDA margin and net debt and net debt leverage, that differ from financial measures reported in conformity with GAAP. The company believes these non-GAAP measures provide useful information to investors. Among other things, they may help investors assess and analyze our operational results and trends of our ongoing operations. Management also uses these non-GAAP measures internally to evaluate the performance of the business and in making resource allocation decisions. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. Reconciliation of non-GAAP financial measures and reported GAAP financial measures are included in the tables below.
Adjusted Gross Profit and Gross Margin Percentage
We define gross profit as total revenue less cost of sales. We define adjusted gross profit as gross profit less royalty revenue sold to a third party, less cost of sales adjustments. We define adjusted gross margin percentage as adjusted gross profit divided by total revenue, less royalty revenue sold to a third party. The following is a reconciliation of GAAP reported gross profit for the for the three months March 31, 2026 and 2025, to adjusted gross profit and adjusted gross margin percentage:
Three Months Ended March 31,
2026
2025
GAAP reported gross profit
$ 785
$ 684
Sold royalty revenue
(9)
—
Cost of sales adjustments
—
1
Adjusted gross profit
$ 776
$ 685
Adjusted gross margin percentage
57.0 %
57.4 %
Adjusted Net Income and Earnings Per Share
We define adjusted net income as net income (loss) excluding amortization of intangible assets, purchase accounting adjustments to inventory, acquisition and divestiture-related charges, including integration and separation costs, severance, goodwill and other asset impairments, gains on sales of assets and related costs, facility exit costs, the impacts from sales of future revenues, gains and losses on mark-to-market adjustments on equity securities, tax valuation allowances, certain litigation-related settlements that we consider to be unusual or infrequent and significant, and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items. We define adjusted earnings per share as adjusted net income divided by the number of weighted-average diluted shares outstanding for the applicable period. The following is a reconciliation of GAAP reported net income and EPS for the three months ended March 31, 2026 and 2025, to adjusted net income and EPS:
Three Months Ended March 31,
2026
Three Months Ended March 31,
2025
Net income (a)
EPS
Net income (a)
EPS
GAAP reported net income and EPS
$ 57
$ 0.11
$ 67
$ 0.13
Cost of sales
—
—
1
0.00
Amortization of intangible assets
138
0.27
128
0.26
Asset impairment, restructuring and other
special charges (1)
16
0.03
9
0.02
Sold royalty revenue
(9)
(0.02)
—
—
Interest expense, net of capitalized interest (2)
14
0.03
—
—
Other expense, net (3)
13
0.03
5
0.01
Income tax expense (benefit) (4)
(25)
(0.05)
(26)
(0.05)
Adjusted net income and EPS
$ 204
$ 0.40
$ 184
$ 0.37
(a)
Adjustments to GAAP reported net income to arrive at adjusted net income for the three months ended March 31, 2026 and 2025, included the following:
(1)
Adjustments of $16 million for the three months ended March 31, 2026, primarily related to $15 million of non-cash shut-down costs for the animal studies portion of our R&D facilities in Monheim, Germany associated with our 2025 Restructuring Plan. Adjustments of $9 million for the three months ended March 31, 2025, included $7 million of upfront payments made in relation to new licensing arrangements.
(2)
Adjustments of $14 million for the three months ended March 31, 2026, related to imputed interest expense on our liability for sale of future revenue.
(3)
Adjustments of $13 million for the three months ended March 31, 2026, primarily related to currency translation losses reclassified from accumulated other comprehensive loss in conjunction with the substantial liquidation of a dormant legal entity, a litigation settlement, and mark-to-market adjustments on equity investments. Adjustments of $5 million for the three months ended March 31, 2025, related to mark-to-market adjustments on equity investments and the impact of hyperinflationary accounting in Turkey.
(4)
Adjustments of $25 million for the three months ended March 31, 2026 primarily represented the income tax expense associated with the adjusted items discussed above. Adjustments of $26 million for the three months ended March 31, 2025, primarily represented the income tax expense associated with the adjusted items discussed above. The adjustments for the three months ended March 31, 2025, also reflect a $35 million benefit related to a discrete tax item recognized during the quarter.
Adjusted EBITDA and Adjusted EBITDA Margin
We define adjusted EBITDA as net income (loss) adjusted for interest expense (income), which includes debt financing charges and imputed interest on our liability for sale of future revenue, income tax expense (benefit) and depreciation and amortization, further adjusted to exclude purchase accounting adjustments to inventory, acquisition and divestiture-related charges, including integration and separation costs, severance, goodwill and other asset impairments, gains on sales of assets and related costs, facility exit costs, revenue sold to a third party, gains and losses on mark-to-market adjustments on equity securities, certain litigation-related settlements which we consider to be unusual or infrequent and significant, and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations.
For the periods presented, we have not made adjustments for all items that may be considered unrelated to our long-term operations. We believe adjusted EBITDA, when used in conjunction with our results presented in accordance with GAAP and its reconciliation to net income (loss), enhances investors' understanding of our performance, valuation and prospects for the future. We also believe adjusted EBITDA is a measure used in the animal health industry by analysts as a valuable performance metric for investors. The following is a reconciliation of GAAP reported net income for the three months ended March 31, 2026 and 2025, to EBITDA, adjusted EBITDA and adjusted EBITDA margin, which we define as adjusted EBITDA divided by total revenue, less royalty revenue sold to a third party, for the respective periods:
Three Months Ended March 31,
2026
2025
GAAP reported net income
$ 57
$ 67
Net interest expense
57
40
Income tax expense (benefit)
30
(7)
Depreciation and amortization
170
161
EBITDA
$ 314
$ 261
Non-GAAP adjustments:
Cost of sales adjustments
$ —
$ 1
Asset impairment, restructuring and other special charges
16
9
Sold royalty revenue
(9)
—
Other expense, net
13
5
Adjusted EBITDA
$ 334
$ 276
Adjusted EBITDA margin
24.5 %
23.1 %
Numbers may not add due to rounding.
Gross and Net Debt and Net Leverage Ratio
We define gross debt as the sum of the current portion of long-term debt and long-term debt excluding unamortized debt issuance costs. We define net debt as gross debt less cash and cash equivalents and finance lease liabilities on the balance sheet. We define our net leverage ratio as net debt divided by our trailing twelve month adjusted EBITDA. We believe our net debt and net leverage ratio are important measures to monitor our financial flexibility, liquidity and capital structure and may enhance investors' understanding of our ability to meet future financial obligations. In addition, a net leverage ratio is a financial measure that is frequently used by investors and creditors. The below calculations do not include covenant-related adjustments that reduce our net leverage ratio. The following is a reconciliation of gross debt to net debt as of March 31, 2026:
Long-term debt
$ 3,918
Current portion of long-term debt
73
Less: Unamortized debt issuance costs
(27)
Total gross debt
4,018
Less: Cash and cash equivalents
428
Less: Finance lease liabilities
255
Net debt
$ 3,335
The following table presents a calculation of our net leverage ratio as of March 31, 2026:
Net debt
$ 3,335
Trailing twelve month adjusted EBITDA
$ 958
Net leverage ratio
3.5
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]
Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected]
Elanco Animal Health Incorporated (ELAN - Free Report) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +16.28%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.13, delivering a surprise of +18.18%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Elanco Animal Health, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $1.37 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 6.93%. This compares to year-ago revenues of $1.19 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Elanco Animal Health shares have added about 1.6% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for Elanco Animal Health?While Elanco Animal Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Elanco Animal Health was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.30 on $1.32 billion in revenues for the coming quarter and $1.03 on $5 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
RadNet (RDNT - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.
This operator of medical diagnostic imaging centers is expected to post quarterly loss of $0.14 per share in its upcoming report, which represents a year-over-year change of +60%. The consensus EPS estimate for the quarter has been revised 20.6% lower over the last 30 days to the current level.
RadNet's revenues are expected to be $564.26 million, up 19.7% from the year-ago quarter.
The animal health company also released better-than-expected first-quarter earnings.
Elanco Stock Rises On Emergency Use Authorization ApprovalsThe recent approval of Elanco’s Negasunt Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil (Coumaphos, Propoxur) covers use against new world screwworm in livestock.
Elanco Animal Health reported first-quarter adjusted earnings of 40 cents, beating the consensus of 35 cents, and within management guidance of 33-36 cents.
Sales increased 15% (+10% organic constant currency growth) to $1.37 billion, beating the consensus of $1.29 billion and management guidance of $1.28 billion-$1.31 billion.
Pet Health Segment Shows Steady GrowthPet Health revenue was $710 million, up 12% (+7% on an organic constant currency basis).
Volume increased 5%, primarily driven by new products, and the addition of two new retail customers benefited parasiticides.
The 2% increase in price was in line with the company’s expectations. The Advantage Family of products and Seresto contributed revenue of $163 million and $159 million, respectively.
U.S. Pet Health achieved 6% growth despite winter storms impacting January and February at the vet clinic, then saw a sharp recovery in March to 8% growth, with April even better.
March was Zenrelia’s largest month yet, with U.S. vet clinic sell-in 30% larger than any other month to date. The company said it is at over 16,000 U.S. vet clinics or over 50% of the total, and the reorder rate is over 80%.
Farm Animal revenue was $642 million, an increase of 18% (+13%).
First quarter volumes were up 11%, driven by strong demand across all species, led by poultry and ruminants. Farm animal organic constant currency revenue growth included a 2% increase from price, compared to the first quarter of 2025.
Adjusted EBITDA was $334 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025. Adjusted EBITDA margin was 24.5% compared with 23.1% a year ago.
Guidance Raised Amid Strong Start To YearIn the earnings conference call, the company said, “With our solid start to the year and accelerating trends into March and April, we are well positioned to raise our top and bottom line outlook for the full year.”
Elanco Animal Health increased its adjusted earnings guidance from $1.00-$1.06 per share to $1.03-$1.09 per share, compared to the consensus of $1.03.
The company also raised its sales guidance from $4.95 billion-$5.02 billion to $5.01 billion-$5.085 billion compared to the consensus of $5 billion.
Elanco Animal Health sees second-quarter adjusted earnings of 25-28 cents versus the consensus of 29 cents, with sales between $1.3-$1.325 billion compared to the Wall Street estimate of $1.32 billion.
ELAN Stock Price Activity: Elanco Animal Health shares were up 9.33% at $25.13 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 323
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
, /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m. ET.
On Tuesday, June 2, Jeff Simmons, president and CEO will present at the William Blair 46th Annual Growth Stock Conference at 3:20 p.m. CT.
Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will be available for a limited time at the conclusion of the event.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Media Contact: Season Solorio (765) 316-0233 [email protected]
Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected]
On May 15, 2026, Elanco Animal Health Inc ELAN shares fell 8.2% today, bringing the current price to $19.96. The stock has experienced considerable volatility recently, trading between a 52-week high of $27.72 and a low of $12.40.
GF Value™ verdict: Current price is $19.96, which is 28.8% above the GF Value™ estimate of $15.50, indicating the stock is overvalued.GF Score™: The stock has a score of 70/100, categorizing it as above average.Most notable signal: The momentum rank is a strong 10/10, indicating robust recent performance. Is ELAN Overvalued or Undervalued? The current price of Elanco Animal Health Inc ELAN at $19.96 is significantly higher than the GF Value™ estimate of $15.50. This suggests that the stock is overvalued by approximately 28.8%. The GF Valuation label indicates that the stock is considered "Modestly Overvalued." This overvaluation presents a risk for potential investors, as the stock may not provide sufficient returns in the near future if it does not meet growth expectations or if market conditions worsen.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. It is essential for investors to consider the margin of safety when investing in stocks, especially those identified as overvalued. In Elanco's case, the substantial gap between current price and GF Value™ raises caution for potential investment.
How Does ELAN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 18.6x 20.8x Elanco's forward P/E ratio of 18.6x is below its 5-year median P/E of 20.8x, suggesting that the stock is trading at a discount compared to its historical valuation. However, this analysis aligns with the GF Value™ verdict of being overvalued, as the current price still exceeds the calculated intrinsic value. The lower forward P/E indicates potential for growth, but it does not negate the risks associated with the current overvaluation.
What Does ELAN's GF Score™ Tell Us? Metric Rating GF Score™ 70 Financial Strength 5/10 Profitability 4/10 Growth 5/10 Valuation 5/10 Momentum 10/10 The GF Score™ of 70/100 indicates that Elanco is positioned above average among its peers. The strongest area is its momentum rank of 10/10, reflecting a strong recent performance. Conversely, the weakest aspects include financial strength and profitability, which are rated at 5/10 and 4/10, respectively. This mixed performance suggests that while the company shows strong short-term momentum, it faces challenges in maintaining long-term financial stability and profitability.
What Are Insiders Doing with ELAN Stock? There have been no insider transactions in the last three months for Elanco Animal Health Inc ELAN . This lack of activity may signal a cautious approach among insiders, possibly reflecting uncertainty about the company’s near-term performance or valuation. Without insider buying to indicate confidence, investors may want to tread carefully.
What This Means for Investors Based on the GF Value™ assessment, Elanco Animal Health Inc ELAN is currently overvalued. The substantial difference between the current price and the estimated intrinsic value suggests that caution is warranted for potential investors. While the stock has shown strong momentum recently, the risks associated with its valuation should be carefully considered.
For the complete analysis, visit the Elanco Animal Health Inc ELAN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is ELAN's GF Score™?
ELAN's GF Score™ is 70/100, indicating that the stock is above average in terms of its potential to generate long-term returns.
Is ELAN overvalued or undervalued?
ELAN is currently overvalued, with its price of $19.96 exceeding the GF Value™ estimate of $15.50 by 28.8%.
What is ELAN's P/E ratio?
ELAN's forward P/E ratio is 18.6x, which is below its 5-year median P/E of 20.8x, indicating that the stock is trading at a discount compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today
Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab Starts controlling itch within 24 hours and is given as an in-clinic injection Select Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomes Meet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their journeys to itch relief Befrena is Elanco's second monoclonal antibody to launch in the U.S. pet health market, joining Trutect™, the first and only approved therapeutic solution to treat canine parvovirus and has been shown to be effective for passive immunity , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection for treatment of canine allergic and atopic dermatitis. The launch comes at a key time, with a longer and more intense allergy season anticipated across the country this year.i With nearly 2 in 3 itchy dogs experiencing worse itch during allergy seasonii, Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours. By neutralizing IL-31, a key cytokine involved in sending itch signals to the brain, Befrena offers a differentiated 6 to 8 weeks dosing interval, providing veterinarians and pet owners with a new level of convenience and efficacy.
Beaux, a 6-year-old Yorkie from Austin, TX before receiving his first Befrena injection on March 31st, 2026
Beaux, a 6-year-old Yorkie from Austin, TX on April 21st, 2026, just 3 weeks after receiving his first Befrena injection Benefits of Befrena:
Offers at least 6 to 8 weeks of itch relief, in contrast to the 4 to 8 weeks of the current market incumbent, lokivetmab Starts controlling itch within 24 hours Given as an in-clinic injection administered by, or under the supervision of, a licensed veterinarian Elanco received approval of Befrena from the U.S. Department of Agriculture (USDA) in December 2025, making it the company's second dermatology product, alongside Zenrelia™ (ilunocitinib tablets), to be approved and launched in the past two years.
Elanco is also now the only pet health company with two USDA approved mAb products – Befrena and Trutect. Trutect is the first and only approved therapeutic solution to treat canine parvovirus.
"The commercial launch of Befrena into the $1.3 billion U.S. canine dermatology marketiii is another exciting milestone in our innovation journey," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "We are seeing positive results from our Early Experience Program veterinarians who have started using Befrena in their clinics and will continue to increase supply of this new monoclonal antibody, as we scale our bioreactors with the anticipated manufacturing ramp-up."
Make Best Friends Better – Meet the First Dogs Treated with Befrena
Nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itch at any point throughout the yearii. Data in Elanco's America's Itchy Dogs Report also found that veterinarians say that itchy dog owners wait too long before bringing in their dog, resulting in raw and infected skin and an irritated dog owner who wants their dog to experience relief quickly.ii
As a part of the Befrena Early Experience Program, select veterinarians and veterinary dermatologists have already started using Befrena in their clinics and seen initial improvements in itchy dogs.
Beaux from Austin, TX was the first dog treated with Befrena after experiencing significant hair loss due to his constant itch.
According to Dr. Matt Lane at Liberty Animal Hospital at Beaux's 3-week checkup appointment, "Beaux is doing amazing, and his owner is excited to see his hair growing back. He stopped itching within 24 hours of receiving the injection and his owner and I are extremely pleased with the results."
Penelope and Zephyr were also treated with Befrena at Gigi's Animal Shelter in Columbus, OH. Both dogs experience seasonal allergies that impact their behavior and quality of life and after discussing with their veterinarian both owners chose Befrena to control their dogs' itch.
"We want to get these dogs relief and make sure they have the most comfortable experience as possible, and I think Befrena shows some real promise for that," said Dr. Meghan Herron, Senior Director of Behavior, Research, and Education at Gigi's.
Zephyr's owner is also a licensed veterinary technician at Gigi's and helped administer Zephyr's injection. You can follow along their journey below.
https://elanco.wistia.com/medias/5nbmg3s2hk
"I have been involved with two clinical trials and the Early Experience Program which has shown Befrena to be a highly safe and effective product," said Dr. Tom Lewis, veterinary dermatologist and founder of Dermatology for Animals, a group of veterinary dermatology clinics committed to caring for pets with allergies. "This will become a very important treatment option for many allergic dogs and I am excited to use Befrena in my clinic."*
"I've used Befrena in a few patients so far and while it's still relatively early, I'm very optimistic and excited about what's going to happen with these cases," said Dr. Jason Pieper, veterinary dermatologist and tenured associate professor of dermatology at Iowa State University College of Veterinary Medicine. "I've had several patients respond very well including one unique case that has failed multiple other treatments for atopic dermatitis. And so far, two weeks after receiving Befrena, this dog's doing quite well, it's wonderful."*
Learn more about Befrena and sign up for future news and webinars at www.befrenaforvets.com.
*Drs. Pieper and Lewis are consultants for Elanco.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
INDICATIONS
Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age.
IMPORTANT SAFETY INFORMATION
Read the package insert, including the Boxed Warning, before using this drug. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.
WARNING: INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of an inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.
i Asthma and Allergy Foundation of America, (2026). 2026 Allergy Capitals. Retrieved from allergycapitals.org.
ii Elanco Animal Health. Data on File. REF-28442
iii Elanco Animal Health. Data on File. REF-29772
Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Media Contact: Season Solorio (765) 316-0233 [email protected]
On May 20, 2026, Elanco Animal Health Inc ELAN shares rose 5.3% today, closing at $20.85. This increase comes after a challenging month, where shares have declined by 11.9%. The stock has fluctuated significantly over the past year, with a 52-week high of $27.72 and a low of $12.40.
GF Value™ verdict: current price is $20.85 vs GF Value™ of $15.52, indicating a 34.3% overvaluation.GF Score™ is 70/100, suggesting an above-average ranking among peers.The most notable signal is insider activity, with insiders purchasing $0.2M worth of shares in the last three months, indicating confidence in the company's future. Is ELAN Overvalued or Undervalued? Based on the current market price of $20.85 compared to the GF Value™ of $15.52, Elanco Animal Health Inc appears to be significantly overvalued, with a margin of safety of 34.3%. This overvaluation suggests that the stock may not be a prudent investment at its current price, as it exceeds the intrinsic value estimated by GuruFocus. The GF Valuation label indicates that the stock is significantly overvalued, which poses a risk for investors if the market corrects itself and aligns closer to the GF Value™.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. The current price being substantially above this value raises concerns regarding potential market corrections, which could lead to a decline in share price.
How Does ELAN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 19.4x 20.8x Currently, Elanco's forward P/E ratio stands at 19.4x, which is slightly below its 5-year median P/E of 20.8x. This indicates that the stock is trading below its historical valuation levels. However, this P/E analysis aligns with the GF Value™ verdict that suggests the stock is overvalued, as a lower forward P/E does not necessarily justify the current market price when compared to intrinsic value.
What Does ELAN's GF Score™ Tell Us? Metric Rating GF Score™ 70/100 Financial Strength 5/10 Profitability 4/10 Growth 5/10 Valuation 5/10 Momentum 10/10 The GF Score™ of 70/100 indicates that Elanco Animal Health Inc is positioned above average compared to its peers. The strongest aspect of the score is the Momentum Rank, which is rated at 10/10, reflecting strong recent performance. However, the weakest areas are in Profitability and Financial Strength, both rated at 4/10 and 5/10 respectively, suggesting concerns in these domains that could impact long-term stability and growth.
What Are Insiders Doing with ELAN Stock? In the last three months, insiders of Elanco Animal Health Inc have purchased $0.2 million worth of shares, with no reported selling activity. This buying trend is generally seen as a positive signal, indicating that those closest to the company have confidence in its future prospects. Such insider buying could reflect management's belief in the company’s potential for growth and suggests that insiders are optimistic about the stock's future performance.
What This Means for Investors Based on the analysis, Elanco Animal Health Inc appears to be overvalued at its current price of $20.85, significantly above the GF Value™ of $15.52. The strong momentum rank and insider buying activity provide some positive signals, but the overall valuation metrics and risk of market correction suggest caution for potential investors.
For the complete analysis, visit the Elanco Animal Health Inc ELAN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is ELAN's GF Score™?
ELAN's GF Score™ is 70/100, indicating an above-average ranking compared to its peers, suggesting potential for higher long-term returns.
Is ELAN overvalued or undervalued?
ELAN is currently overvalued, with a GF Value™ of $15.52 compared to a market price of $20.85, indicating a significant premium.
What is ELAN's P/E ratio?
ELAN's forward P/E ratio is 19.4x, which is below its 5-year median P/E of 20.8x, aligning with the conclusion that the stock is overvalued relative to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
, /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry.
According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.
Pet owner data 2026. Stable Expectations for Pet Owner Spend: 91% of pet owners have at least maintained their spending on pet health and wellness products in recent years, with 38% of pet owners increasing spend. This remains stable with February research prior to rising fuel prices. Increasing Pet Care Spend Despite Rising Costs of Living: 31% of pet owners say they've increased spending on their pets' health and wellness in the past three months, despite increasing economic challenges. Further, 90% of pet owners expect their spending to stay the same or increase (37%) in the year ahead. Pet Health & Wellness as a Top Priority and Core Expenditure: 95% of pet owners see pet health and wellness care as a priority that they will not reduce due to economic pressure. Even when consumers face personal financial challenges, they are willing to cut spending on themselves – dining out, travel – before their pets. In fact, pet health and wellness was the last item in the surveyed categories that consumers would cut if required to reduce expenses. Elanco's latest research reveals a powerful and enduring shift in consumer behavior shaped by a new kind of pet owner – one who is more engaged, more informed and more empowered than ever before. Pets are no longer just companions – they're family. With fewer kids and more pets, pet owners are demonstrating an increased expectation of care and desire for longer, healthier lives for their pets. This profound commitment translates directly into a strong and durable willingness to invest in their wellbeing, with 88% of pet parents saying their pet's happiness and wellbeing is as important as their own.
"Our research consistently shows that pet care is not a discretionary expense; it's a deeply emotional and highly prioritized investment for pet parents," said Bobby Modi, Executive Vice President, U.S. Pet Health and Digital Transformation. "Pet owners are demonstrating an unwavering commitment to their animals' health, driving demand for innovative, high-quality solutions. This fundamental consumer trend underpins the resilience and growth potential of the companion animal industry, and Elanco is strategically positioned to capitalize on it."
These findings reinforce the broader industry data showing the animal health industry is one of the most compelling and resilient sectors, with a 20-year track record of continual growth, averaging about 5% annually. Elanco estimates the industry expanded by 7% in 2025. Deep consumer commitment to pets and a surging demand for animal protein are driving sustained growth. With a long runway ahead, the animal health industry is projected to grow from $42 billion in 2025 to $60 billion in the next decade.
Key pet health trends further amplify this opportunity:
Omnichannel Access & Convenience: Modern pet owners seek convenience and diverse access points for care. While vet visit volumes may fluctuate, spending on vet services continues to grow, indicating a strong willingness to spend on innovation. Further, approximately 40% of pet care sales are subscription-based. Additionally, many consumers spend outside the vet clinic. The 2024 APPA National Pet Owners Survey indicated approximately one-third of all dog and cat owners didn't take their pet to a veterinarian in the previous year. Elanco is well-positioned with an omnichannel approach to meet pet owners where, when, and how they choose to engage. Comprehensive Portfolios & Innovation: Pet owners are willing to spend on innovation, which creates the value that drives industry pricing. Elanco is well-positioned with its market-leading growth in U.S. Pet Health through a basket of innovation, #1 standing in OTC1 and status as just one of two industry providers with a complete portfolio. Expanding Diagnostic Opportunities: Currently, only one in five pet visits includes diagnostics, meaning the true spectrum of disease is often unknown. As diagnostics expand what can be detected, and AI accelerates what can be learned, the opportunity to improve pet health and drive value is substantial. Elanco remains committed to providing pet owners with a wide range of innovative solutions at a variety of price points where they want to shop, that deliver on pet owners' desire to help their pets live longer, healthier, more active lives.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning expected consumer trends, market dynamics and industry growth. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, and additional factors that could cause actual results to differ materially from forward-looking statements described in the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
________________________________
1 Internal estimates based on multiple data sources, as provided with our financial results reported on May 6, 2026
Zoetis is largest producer of medicines and vaccinations for pets and livestock. Cramer stated that he prefers Elanco Animal Health Inc (NYSE:ELAN) in this industry. "That would be the one in animal health that I'd like you to be in," he said.
Regarding the midstream energy company Energy Transfer LP Unit (NYSE:ET), the Lightning Round host said that the company is in "a terrific situation."
"I like it very much. I think it is inexpensive and has a good dividend," he added.
Price Action:
Zoetis shares tanked 1.53% to close at $76.39 on Tuesday. Shares of Elanco Animal Health Amkor declined by 0.17% to settle at $23.63 on Tuesday. Energy Transfer shares were up 1.40% to close at $19.54 on Tuesday. Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States
New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae , /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i
The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii
"New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods," said Jeff Simmons, President and CEO, Elanco Animal Health. "We want to thank the FDA, EPA and USDA, for all their work to prepare for this threat. We're committed to supporting our customers during this challenging time by delivering innovation, scientific expertise, and available resources to help treat New World screwworm and support the health and well-being of animals."
With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, Elanco is working alongside the U.S. animal health industry to help them fight against this parasite, offering a portfolio of options for pets and livestock that can help treat New World screwworm larvae infestations.
Available Elanco Treatment and/or Prevention Options
Product Name
Indication
Species
Regulatory Status
Credelio Quattro™- CA1
(lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets)
Treats New World screwworm larvae infestations
Dogs
FDA Conditional Approval
Credelio™ (lotilaner)
Treats New World screwworm larvae infestations
Dogs
FDA Emergency Use Authorization (EUA)
Credelio™ CAT (lotilaner)
Treats New World screwworm larvae infestations
Cats
FDA Emergency Use Authorization (EUA)
Negasunt™ Powder (coumaphos, propoxur, and sulfanilamide topical powder)
Treats and Prevents New World screwworm larvae infestations
Variety of Livestock and other Species
FDA Emergency Use Authorization (EUA)
Tanidil™ (Coumaphos, Propoxur)
Prevents and Controls New World screwworm larvae infestations
Variety of Livestock and other Species
EPA Section 18 Emergency Exemption
Catron® IV (Permethrin)
Kills and controls screwworm fly and maggots
Livestock
EPA Approved
Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.
As New World screwworm enters the United States, Elanco is committed to working alongside producers as they continuously evolve management practices and to help them implement prevention and treatment protocols to use the right product at the right time.
To learn more about Elanco's ongoing efforts and historical perspective on New World screwworm, please visit our previous coverage:
Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs To learn more about New World screwworm (NWS) using the following resources:
USDA NWS Alert and Fact Sheet NCBA NWS Resources FDA Information for Veterinarians on NWS About Elanco Animal Health
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Indications for Credelio Quattro/Credelio Quattro-CA1
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.
Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information for Credelio Quattro/Credelio Quattro-CA1
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.
Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.
For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.
Emergency Use Authorization of Credelio (lotilaner) Chewable Tablets for New World Screwworm (NWS)
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) chewable tablets for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Credelio is not approved for this use.
Credelio (lotilaner) is approved for other uses in dogs and puppies.
For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.
Limitations of Authorized Use
Credelio (lotilaner) chewable tablets is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) chewable tablets under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Indications for Credelio
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.
Important Safety Information for Credelio
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.
Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS)
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.
Credelio CAT is approved for other uses.
For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.
Limitations of Authorized Use
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Indications for Credelio CAT
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater.
Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater.
Important Safety Information for Credelio CAT
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian.
Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)
WARNING: Neurotoxicity. Read full Fact Sheet for complete information.
Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing. Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters. This product is toxic to mammals, birds, fish, and aquatic invertebrates. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.
For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).
For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.
Limitations of Authorized Use
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.
Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.
A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.
A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.
Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.
To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.
Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.
Federal law prohibits the extra-label use of this drug.
Additional Important Safety Information
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.
Important Information about Tanidil
Tanidil™ is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.
For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.
Read the entire label. This product must be used strictly in accordance with this label's precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.
Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.
